Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period.

Trial Profile

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SCALE; SCALE-Diabetes
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 21 Jul 2019 This trial has been completed in United Kingdom as per the European Clinical Trials Database record.
    • 01 Nov 2016 Results of population pharmacokinetic analysis in obese patients of this and other two trials published in the Clinical Pharmacokinetics
    • 19 May 2016 Results of a post-hoc population pharmacokinetic analysis from SCALE-Diabetes and SCALE-Obesity and Pre-diabetes trials (n=2923) published in the Clinical Pharmacokinetics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top